Test results after stem cell transplant for multiple myeloma can confuse patients and doctors about

August 10, 2017
Dr. Gurmukh Singh, vice chair of clinical affairs for the Department of Pathology and Walter L. Shepeard Chair in Clinical Pathology at the Medical College of Georgia at Augusta University. Credit: Phil Jones

It's a cancer of the plasma cells, which normally make an array of antibodies that protect us from infection.

With multiple myeloma, the start primarily producing instead a singular product, called a monoclonal antibody, or M spike, that leaves vulnerable for serious infections, like pneumonia, and can even eat away at their bones.

Sophisticated laboratory tests used to both diagnose the disease then follow treatment response, can send confusing messages to patients and their physicians, particularly after to try to restore a healthy antibody mix, says Dr. Gurmukh Singh. Singh, vice chair of clinical affairs for the Department of Pathology and Walter L. Shepeard Chair in Clinical Pathology at the Medical College of Georgia at Augusta University, is corresponding author of the study highlighting reasons for potential confusion in the Journal of Clinical Medicine Research.

The tests, serum protein electrophoresis and serum immunofixation electrophoresis, or SPEP/SIFE, and serum free light chain assay, or SFLCA, separate proteins into groups according to their electrical charge.

The M spike stands out as a distinctive, dense band of color among the layers of protein groups, while typical antibody levels create bands of lighter smears.

But after stem cell therapy, which first destroys cancerous then restores healthy ones, follow up profiles often yield a lineup of —called an oligoclonal pattern—that can look eerily similar to the M spike.

The confusion comes because there again may be a prominent and likely short-lived band of proteins that emerges as the antibody mix begins, ideally, to normalize.

"We want to emphasize that oligoclonal bands should mostly be recognized as a response to treatment and not be mistaken as a recurrence of the original tumor," Singh says.

The key clarifier appears to be the location of the malignant, monoclonal spike when the diagnosis is made compared to the location of new spikes that may show up after stem cell therapy in these oligoclonal bands, says Singh.

"If the original peak was at location A, now the peak is location B, that allows us to determine that it is not the same abnormal, malignant antibody," Singh says, pointing toward different before and after treatment profiles on a patient.

Normally antibodies spread out in a usual sequence in these studies. "If it's in a different location, it's not the same protein," reiterates Singh. "If the location is different, this is just a normal response of recovery of the bone marrow that could be mistaken for recurrence of the disease," Singh says of the oligoclonal bands that can also temporarily show up in response to an infection.

He notes while the prominent bands are typically short-lived following treatment, the recognition that they are non-malignant may occur only in retrospect.

For the study, Singh and his team looked at lab and clinical data on 251 patients with multiple myeloma treated from January 2010 to December 2016; 159 of those patients received autologous . Each patient had at least three tests, and at least two of the tests were following their transplant.

They found the incidence of oligoclonal patterns was significantly higher in patients who had a stem cell transplant than the patients who had chemotherapy alone: 57.9 percent compared to 8.8 percent. Only five of the 159 patients who received a transplant had an oligoclonal pattern before treatment but 92 had one afterward. More than half of the the oligoconal patterns developed within the first year following a transplant. The earliest pattern was detected at two months - as soon as the first post-transplant tests were done—and a few occurred as long as five years later.

Autologous stem cell therapy is not considered curative for most patients with . There is no clear cause of the disease but the risk does increase at age 40, Singh says.

Explore further: Excessive tests don't benefit patient, do increase cost in age-related immune disorder

Related Stories

Excessive tests don't benefit patient, do increase cost in age-related immune disorder

April 26, 2016
A series of tests physicians routinely order to help diagnose and follow their patients with an elevated antibody level that is a marker for cancer risk, often do not benefit the patient but do increase health care costs, ...

Preliminary study: Antibody therapy reduces cancer stem cells in multiple myeloma

April 15, 2016
An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to ...

New finding affecting immune reconstitution related to B cells

May 15, 2017
Researchers from the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles examined the mechanisms of B cell immune reconstitution in pediatric patients who had undergone bone marrow transplantation ...

Antibody Tx reduces graft-vs-host post stem cell transplant

January 7, 2016
(HealthDay)—Antibody therapy before stem cell transplant may benefit patients with acute leukemia, according to research published in the Jan. 7 issue of the New England Journal of Medicine.

Study shows benefit of new maintenance therapy for multiple myeloma

May 11, 2012
Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called ...

Lamprey-derived antibody specifically recognizes human plasma cells

March 17, 2016
Antibody-secreting plasma cells arise from B cell precursors and are essential for adaptive immune responses against invading pathogens. Plasma cell dysfunction is associated with autoimmune and neoplastic disorders, including ...

Recommended for you

Breast cancer researchers find bacteria imbalance link

October 19, 2017
Researchers in the United States have uncovered differences in the bacterial composition of breast tissue of healthy women versus those with breast cancer.

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

US regulators approve 2nd gene therapy for blood cancer

October 19, 2017
U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults.

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.